Search research articles
Contact Us
Filters
Showing results (31-40 of 231) with videos related to
Page
of 24
Sort By:
European Journal of Haematology
|
April 13, 2006
Medium-term results of percutaneous vertebroplasty in multiple myeloma
Luis Ramos, José Antonio de Las Heras, Sergio Sánchez, et al.
Blood Advances
|
May 10, 2023
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 11, 2024
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study
Maria-Victoria Mateos, Katja Weisel, Joris Diels, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 14, 2025
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial
Katja Weisel, Maria-Victoria Mateos, Ola Landgren, et al.
Hematological Oncology
|
February 16, 2018
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials
Maria-Victoria Mateos, Hartmut Goldschmidt, Jesus San-Miguel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 18, 2011
The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells
Lucía López-Corral, Norma C Gutiérrez, Maria Belén Vidriales, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 13, 2020
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies
Michele Cavo, Meletios A Dimopoulos, Jesus San-Miguel, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 14, 2026
Real-World Treatment Patterns and Outcomes for Patients With Relapsed/Refractory Multiple Myeloma and Prior Exposure to Lenalidomide and Proteasome Inhibitors in the United States
Luciano J Costa, Sandhya Nair, Marguerite O'Hara, et al.
Oncotargets and Therapy
|
September 3, 2025
The Role of CELMoD Agents in Multiple Myeloma
Niels W C J van de Donk, Nizar J Bahlis, Charlotte Pawlyn, et al.
Blood Cancer Journal
|
February 7, 2025
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Pralay Mukhopadhyay, Hesham A Abdullah, Joanna B Opalinska, et al.
Page
of 24
Search research articles
Search
Showing results (31-40 of 231) with videos related to
Sort By:
Page
of 24
European Journal of Haematology
|
April 13, 2006
Medium-term results of percutaneous vertebroplasty in multiple myeloma
Luis Ramos, José Antonio de Las Heras, Sergio Sánchez, et al.
Blood Advances
|
May 10, 2023
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 11, 2024
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study
Maria-Victoria Mateos, Katja Weisel, Joris Diels, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 14, 2025
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial
Katja Weisel, Maria-Victoria Mateos, Ola Landgren, et al.
Hematological Oncology
|
February 16, 2018
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials
Maria-Victoria Mateos, Hartmut Goldschmidt, Jesus San-Miguel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 18, 2011
The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells
Lucía López-Corral, Norma C Gutiérrez, Maria Belén Vidriales, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 13, 2020
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies
Michele Cavo, Meletios A Dimopoulos, Jesus San-Miguel, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 14, 2026
Real-World Treatment Patterns and Outcomes for Patients With Relapsed/Refractory Multiple Myeloma and Prior Exposure to Lenalidomide and Proteasome Inhibitors in the United States
Luciano J Costa, Sandhya Nair, Marguerite O'Hara, et al.
Oncotargets and Therapy
|
September 3, 2025
The Role of CELMoD Agents in Multiple Myeloma
Niels W C J van de Donk, Nizar J Bahlis, Charlotte Pawlyn, et al.
Blood Cancer Journal
|
February 7, 2025
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Pralay Mukhopadhyay, Hesham A Abdullah, Joanna B Opalinska, et al.
Page
of 24